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Background. Onchocerciasis elimination through mass drug administration (MDA) is hampered by coendemicity of Loa loa, as 
people with high L. loa microfilariae (mf) density can develop serious adverse events (SAEs) after ivermectin treatment. We assessed 
the geographical overlap of onchocerciasis and loiasis prevalence and estimated the number of coinfected individuals at risk of post-
ivermectin SAEs in West and Central Africa from 1995 to 2025.
Methods. Focusing on regions with suspected loiasis transmission in 14 countries, we overlaid precontrol maps of loiasis and 
onchocerciasis prevalence to calculate precontrol prevalence of coinfection by 5 km2 × 5 km2 pixel, distinguishing different categories 
of L. loa mf intensity. Using statistical and mathematical models, we predicted prevalence of both infections and coinfection for 2015 
and 2025, accounting for the impact of MDA with ivermectin.
Results. The number of people infected with onchocerciasis was predicted to decline from almost 19 million in 1995 to 4 million 
in 2025. Of these, 137 000 people were estimated to also have L. loa hypermicrofilaremia (≥20 000 L. loa mf/mL) in 1995, declining 
to 31 000 in 2025. In 2025, 92.8% of coinfected cases with loiasis hypermicrofilaremia are predicted to live in hypoendemic areas 
currently not targeted for MDA.
Conclusions. Loiasis coinfection is a major concern for onchocerciasis elimination in Africa. We predict that under current 
strategies, at least 31 000 coinfected people still require treatment for onchocerciasis in 2025 while being at risk of SAEs, justifying 
continued efforts in research and development for safer drugs and control strategies.
Keywords. Loa loa; onchocerciasis; ONCHOSIM; mass drug administration; serious adverse events.
In 2012 the World Health Organization targeted onchocerci-
asis, also known as river blindness, for elimination through pre-
ventive chemotherapy interventions. Onchocerciasis is caused 
by the filarial nematode Onchocerca volvulus and is transmitted 
by black flies (genus Simulium). Onchocerciasis has a long 
history of control. The Onchocerciasis Control Programme 
(1974–2002) in West Africa started with regional vector con-
trol, later supplemented by mass drug administration (MDA) 
with ivermectin. The African Programme for Onchocerciasis 
Control (APOC, 1995–2015) subsequently initiated MDA in 19 
additional African countries. In 2016, about 132 million people 
at risk for O. volvulus infection in Africa were treated with iver-
mectin [1].
The elimination of onchocerciasis is hampered by 
coendemicity of loiasis (African eye worm), another filarial in-
fection present in West and Central Africa. People with high 
Loa loa microfilarial (mf) densities can develop potentially 
fatal serious adverse events (SAEs) after ivermectin treatment. 
The pathogenesis of postivermectin L.  loa–related neurolog-
ical complications is not fully understood but is most likely a 
combination of mechanical blockage of capillaries by large 
numbers of L.  loa mf paralyzed by the drug and vascular en-
dothelial changes associated with the destruction of mf [2, 3]. 
Ivermectin can induce marked adverse effects with a functional 
impairment that lasts several days in those harboring >8000 mf/
mL blood and unconsciousness, coma, and death in individuals 
with >30 000 mf/mL levels prior to treatment [2, 4, 5]. The prob-
ability of SAEs after ivermectin intake increases from approxi-
mately 0.7% in individuals with 30 000 mf/mL to approximately 
7% in individuals with L.  loa counts of 50 000 mf/mL [3]. As 
the benefits of treatment were considered to outweigh the risk 
of SAEs, coendemic areas with high onchocerciasis prevalence 
were nevertheless targeted for MDA with ivermectin, although 
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fear for SAEs sometimes resulted in low treatment coverage [6]. 
However, coendemic areas with low onchocerciasis prevalence 
have remained untreated to date and might be in need of alter-
native strategies.
To understand the need for and feasibility of alternative 
strategies for onchocerciasis elimination in loiasis-endemic 
areas, we assessed the extent of coendemicity and estimated 
the number of coinfected individuals, including people with 
such high L.  loa mf intensity levels that ivermectin treatment 
is considered unsafe. We combined empirical data using mul-
tiple sources with statistical and mathematical models to esti-
mate how the number of onchocerciasis, loiasis, and coinfection 
cases change over time since precontrol levels up to 2025.
METHODS
General Approach
To estimate the number of people with onchocerciasis–lo-
iasis coinfection in Africa, we first overlaid 5 km2 ×  5 km2 
resolution raster precontrol maps of loiasis and onchocer-
ciasis prevalence with rural population density data from 
1995. For each raster cell, we then used predictive mod-
eling approaches to assess likely changes in the prevalence 
of both infections thanks to locally implemented MDA with 
ivermectin. Predictions for 2015 and 2025 were combined 
with raster maps of estimated population density for the 
same years, and results were subsequently aggregated over 
all raster cells within defined target areas. Below, we de-
scribe the methods used to estimate the impact of MDA with 
ivermectin on the 2 infections. A detailed methodology de-
scription, including the definitions applied, is provided in 
Supplement S1, Table S1.
Geographical Scope of the Analysis
The geographical scope of this analysis includes areas that were 
surveyed for L.  loa endemicity across APOC countries using 
the rapid assessment procedure for loiasis (RAPLOA) pro-
cedure [7, 8]. RAPLOA surveyed areas across countries and 
APOC projects that were suspected to be endemic of loiasis. See 
Supplement S1, Figure S1 for RAPLOA-surveyed areas that are 
coendemic for onchocerciasis.
Data
Loiasis Maps
We used loiasis prevalence maps based on RAPLOA surveys 
that were performed by APOC to identify areas where SAEs 
might occur [4, 9, 10]. A  loiasis prevalence raster map was 
previously generated by geostatistical kriging analysis of the 
RAPLOA data for all potentially endemic areas in 14 coun-
tries [11]. We updated this map to capture new RAPLOA data 
from Nigeria and Angola (Supplement S1, Table S2). The up-
dated map is shown with onchocerciasis overlap in Figure 1, 
and a loiasis-only version is included in Supplement S1, Figure 
S3, and section 3.2. Next, we used the prevalence of history of 
eye worm from the RAPLOA map to estimate the proportion 
of people in each L. loa mf count intensity category (≥8000 to 
<20 000 mf/mL; ≥20 000 to <30 000 mf/mL; ≥30 000 mf/mL) 
using a statistical model as described in Supplement S1, section 
3.4, and Figure S4.
Onchocerciasis Maps
We used previously published maps based on rapid epidemio-
logical mapping of onchocerciasis (REMO) [12, 13]. A previous 
model-based geostatistical analysis of REMO data [12] resulted 
in a raster map of the precontrol prevalence of nodules in 
APOC countries (Figure 1) and some newly added extensions 
(Figure S2 and Supplement S1, section 3.3 in). We converted the 
precontrol nodule prevalence map into a 5 km2 × 5 km2 map of 
precontrol O. volvulus mf prevalence in the general population 
using methods described elsewhere [14, 15].
We linked each raster cell to its APOC project (implemen-
tation unit for MDA, see definitions in Supplement S1, section 
1)  and related information on project treatment history and 
expected future treatment scenario. Briefly, nearly all oncho-
cerciasis hyper- and mesoendemic areas had started annual or 
sometimes biannual MDA by 2013 (up to which year we have 
reported treatment history). For the few projects that had not 
yet started MDA by 2013, we followed the assumptions of Kim 
et al [16], with some adaptations described in Supplement S1, 
section 3.5, and Supplement S3.
Impact of MDA on Loiasis
Based on published studies [17–19], we assume that MDA 
causes a change in the L.  loa mf count frequency distribu-
tion. In our main analysis, we assumed that MDA causes a 
change in the L. loa mf count frequency distribution among 
the population that received a first ivermectin treatment ac-
cording to a Markov transition matrix derived from Gardon 
et  al [17] (Table 1). We assumed that the L.  loa mf count 
frequency distribution was sustained after subsequent treat-
ment without any further changes. After applying the tran-
sition matrix per pixel, linear interpolation was carried out 
to categorize the data into the required L.  loa mf intensity 
classes: mf-negative; >0 to <8000; ≥8000 to <20 000; ≥20 000 
to <30 000; ≥30 000 mf/mL (see Supplement S1, section 4.1). 
We generated raster maps of the predicted prevalence of 
L. loa hypermicrofilaremia (≥20 000 mf/mL) for 1995, 2015, 
and 2025. The cutoff of L. loa mf loads ≥20 000 mf/mL has 
been used as part of a pilot study on the efficacy of a “test-
and-not-treat” (TNT) strategy in order to prevent not only 
the SAEs but also to reduce the incidence of marked effects 
(with functional impairment for several days) that could 
have had an impact of the adherence of the population to the 
strategy [20]. We focused our analyses on L.  loa mf preva-
lence rates of 20 000 mf/mL and above.
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Impact of MDA on Onchocerciasis
We used the mathematical model ONCHOSIM [21–23] to pre-
dict how O.  volvulus mf prevalence would change over time 
due to ivermectin mass treatment for a predefined set of dif-
ferent precontrol endemicity levels, up to 30 years of MDA, and 
various treatment coverage levels (Supplement S1, section 4.2). 
These simulations were used for each raster cell to define the 
likely trend in prevalence over time, considering the local treat-
ment history (start date of MDA, achieved coverage, treatment 
frequency) as explained by Tekle et al [14]. We generated maps 
Figure 1. Map of the estimated precontrol overlap between the prevalence of palpable onchocercal nodules and the prevalence of a history of eye worm in African 
Programme for Onchocerciasis Control countries. Abbreviations: CAR, Central African Republic; DRC, Democratic Republic of Congo. 
Table 1.   Transmission Matrix Relating the Loa loa Microfilariae (mf) Count Frequency Distribution After a Single Treatment With Ivermectin to the 
Pretreatment mf Count Based on Combined 6 and 12 Months Follow-up Data from Gardon et al 1997 [17]
L. loa mf Intensity Category, Pretreatment
Fraction of Population by L. loa mf Intensity Category, Posttreatment
Total No. 0 1–100 >100–500 >500–2000 >2000–10 000 >10 000–30 000 >30 000
0 90 0.978 0.022 0 0 0 0 0
1–100 84 0.857 0.131 0.012 0 0 0 0
>100–500 72 0.500 0.306 0.139 0.056 0 0 0
>500–2000 52 0.365 0.192 0.365 0.077 0 0 0
>2000–10 000 83 0.120 0.084 0.169 0.434 0.193 0 0
>10 000–30 000 84 0.060 0.024 0.071 0.167 0.595 0.083 0
>30 000 68 0 0 0.029 0.059 0.485 0.382 0.044
For clarity, numbers are rounded up to 3 decimal places.
Abbreviation: L. loa, Loa loa; mf, microfilariae.
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of the predicted prevalence of O.  volvulus infection for 1995, 
2015, and 2025.
Estimating the Prevalence of Coinfections
Combining estimates of the proportion of people in different 
L. loa mf intensity frequency classes and the O. volvulus infec-
tion prevalence, we estimated the prevalence of coinfections 
and, in particular, those with high L. loa mf intensity. By doing 
this per 5 km2 × 5 km2 raster cell, we accounted for any spa-
tial correlation between the prevalence of O. volvulus and L. loa. 
Within each raster cell, we assumed that the probability of an 
individual being mf-positive for O.  volvulus was independent 
of the probability that the individual was mf-positive for L. loa. 
The probability distribution per L.  loa mf intensity class for 
pixels in O. volvulus endemic and nonendemic areas was multi-
plied by the total population size for 1995, 2015, and 2025. See 
Supplement S1, section 3.6, for more information on the source 
of population data.
Uncertainty Analysis
We calculated 90% Bayesian credible intervals around the 
total estimated number of cases with onchocerciasis, loi-
asis, or coinfection with ≥20 000 L.  loa mf/mL in the geo-
graphical area of interest (aggregated over 600 200 pixels), 
accounting for uncertainty in key inputs for our analysis 
through a Monte Carlo approach. For a detailed description 
of this analysis, please see Supplement S1, section 4.3, and 
Figure S5.
Sensitivity Analysis
We performed a univariate sensitivity analysis to assess how 
results are influenced by 2 key assumptions: the impact of an-
nual MDA on L. loa and the chosen critical threshold used for 
identifying cases with loiasis hypermicrofilaremia. Alternative 
assumptions for the impact of MDA on loiasis, in addition to 
the assumption described above, include ivermectin reduces 
the prevalence and intensity of L.  loa mf after each repeated 
treatment with ivermectin (according to the Gardon matrix), 
resulting in an exponential effect of repeated treatments on 
L. loa mf, and ivermectin has no effect at all on the intensity and 
prevalence of L.  loa microfilaremia. The critical threshold for 
identifying hypermicrofilaremic L. loa infections was ≥20 000 
mf/mL in our baseline analysis. Alternative values considered 
were ≥8000 mf/mL and ≥30 000 mf/mL.
RESULTS
Total Number of L. loa Microfilaremic and Hypermicrofilaremic Cases
The total number of people living in L. loa-mapped areas was 
81 million in 1995 and is predicted to increase to 169 million 
in 2025 (Table 2; Supplement S2, Table S1). For 1995, we pre-
dict that approximately 3.7 million people (4.5%) were infected 
with L. loa mf (any intensity) of whom 558 000 were infected 
with L. loa hypermicrofilaremia (0.7% of the population; 15.1% 
of all L.  loa mf cases). The total absolute number of L.  loa 
microfilaremic and hypermicrofilaremic cases is expected to 
increase to more than 6 million and 684 000, respectively, by 
Table 2.  Overview of Projections of the Number of Onchocerca volvulus, Loa loa, and Coinfected Cases for 1995, 2015, and 2025 
1995 2015 2025
Total number of cases in Loa loa-mapped areas
 Total population 81 331 134 823 169 257
 No. (%) of people with any L. loa mf intensity 3698 (4.5) [3690–3714] 5017 (3.7) [4994–5039] 6382 (3.8) [6351–6412]
 No. (%) of people with L. loa hypermicrofilaremia 558.3 (0.7) [554.2–562.4] 566.3 (0.4) [560.9–571.7] 683.8 (0.4) [676.9–691.1]
Total number of cases in L. loa-mapped areas that are endemic for onchocerciasis
 Areas where MDA is applied
  Total population 50 011 82 472 103 541
  No. (%) of people with Onchocerca volvulus mf 17 156 (34.3) [17 105–17 208] 10 940 (13.3) [10 893–10 986] 982.0 (0.9) [973.4–991.2]
  No. (%) of people with any L. loa mf intensity 2093 (4.2) [2080–2105]  2356 (2.9) [2343–2370]  2799 (2.7) [2782–2818]
  No. (%) of people with L. loa hypermicrofilaremia 287.5 (0.6) [284.6–290.3] 118.5 (0.1) [116.3–120.8] 83.9 (0.08) [83.0–84.9]
  No. (%) of coinfected cases with any L. loa mf intensity 865.7 (1.7) [859.1–872.1] 484.6 (0.6) [479.7–489.9]  64.1 (0.06) [62.6–65.7]
  No. (%) of coinfected cases with L. loa hypermicrofilaremia 122.3 (0.2) [120.8–123.8] 34.2 (0.04) [33.2–35.2] 2.2 (0.002) [2.2–2.3]
 Areas where MDA is not applied (hypoendemic for onchocerciasis; MDA contraindicated according to MEC/TCC guidelines because of suspected loiasis 
coendemicity)
  Total population 8473 13 945 17 404
  No. (%) of people with O. volvulus mf 1612 (19.0) [1593–1629] 2651 (19.0) [2623–2682] 3302 (19.0) [3264–3338]
  No. (%) of people with any L. loa mf intensity 508.2 (6.0) [503.1–513.3] 815.7 (5.8) [807.3–824.3] 1004 (5.8) [993.3–1014]
  No. (%) of people with L. loa hypermicrofilaremia 81.1 (1.0) [79.6–82.7] 128.9 (0.9) [126.3–131.6] 157.8 (0.9) [154.5–160.9]
  No. (%) of coinfected cases with any L. loa mf intensity 93.2 (1.1) [91.0–95.5] 149.7 (1.1) [146.4–153.1] 183.9 (1.1) [180.1–188.0]
  No. (%) of coinfected cases with L. loa hypermicrofilaremia 14.9 (0.2) [14.3–15.5] 23.7 (0.2) [22.8–24.6] 28.9 (0.2) [27.9–30.0]
The percentages between parentheses in each row are based on the total number of people living in the respective areas. Absolute number of cases are provided in thousands. In square 
brackets are 90% Bayesian credible intervals.
Abbreviations: MDA, mass drug administration; MEC/TCC, Mectizan Expert Committee/Technical Consultative Committee; mf, microfilariae.
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2025, with a respective prevalence of 3.8% and 0.4%. By 2025, 
the proportion of L. loa hypermicrofilaremics among all L. loa-
infected cases would be 10.7%.
Total Number of Cases in L.  loa-Mapped Areas That Are Endemic for 
Onchocerciasis
A large part of the L.  loa-mapped areas is onchocerciasis en-
demic; about 70% of the mapped population are expected to be 
in onchocerciasis-endemic areas (approximately 58.5 million 
people in 1995, growing to approximately 121 million in 2025), 
and a large part of that population (85.5%) will have likely bene-
fited from MDA by 2025 (Table 2; Supplement S2, Tables S2–S4). 
We predict that the overall O. volvulus mf prevalence in treated 
areas coendemic for loiasis will substantially decrease from 34.3% 
in 1995 to 0.9% in 2025. We further predict a reduction in the 
proportion of L.  loa mf cases over time in treated areas (from 
4.2% in 1995 to 2.7% in 2025), but an increase in the absolute 
number (from 2.1 million in 1995 to 2.8 million in 2025) due to 
population growth. For L. loa hypermicrofilaremia, we expect a 
decline in both the prevalence (from 0.6% in 1995 to 0.08% in 
2025) and absolute number of cases (287 000 in 1995 to 84 000 
in 2025; Table 2). By 2025, we predict that about 2000 coinfected 
cases with L. loa hypermicrofilaremia will remain in treated areas. 
This represents only 0.002% of the total population and 0.2% of 
all onchocerciasis patients in these areas. A further breakdown of 
the number of cases by country, precontrol endemicity, and year 
of treatment initiation can be found in Supplement S2.
Between 1995 and 2025, the total population living in 
onchocerciasis-hypoendemic areas coendemic for loiasis where 
MDA with ivermectin is contraindicated according to Mectizan 
Expert Committee/Technical Consultative Committee guide-
lines is expected to grow from more than 8 million to 17 
million (Table 2). Contrary to the situation in treated areas, 
we predict that the number of cases (onchocerciasis, loiasis, 
coinfections) will increase over time proportionally to popula-
tion growth. By 2025, we expect 29 000 coinfected cases with 
L. loa hypermicrofilaremia in these hypoendemic areas if they 
remain untreated. This implies that 0.2% of the total population 
in hypoendemic areas and 0.9% of all onchocerciasis patients 
in these areas will be at risk of SAEs. As a result of the massive 
decline in the number of cases in treated areas and the increase 
in cases in untreated areas, we estimate that by 2025, 77.1% and 
92.8% of all O. volvulus mf-positive cases and coinfected cases 
with L. loa hypermicrofilaremia, respectively, will live in areas 
where ivermectin treatment is currently contraindicated. The 
risk of coinfection with L. loa hypermicrofilaremia is predicted 
to remain stable in untreated areas over time.
Onchocerciasis–Loiasis Maps
Figure 2 maps the expected prevalence of hypermicrofilaremic 
L. loa cases, showing a substantial decline over time, particularly 
in the Democratic Republic of Congo (DRC) and Cameroon. 
However, we still expect sites with a hypermicrofilaremic L. loa 
prevalence of between 3% and 9% in 2025, for example, in 
Gabon, the Central African Republic (CAR), Cameroon, and 
the Republic of Congo.
Figure 2. Maps showing the estimated prevalence of L. loa hypermicrofilaremia 
(≥20  000 mf/mL) in L.  loa-mapped areas for 3 time points: 1995, precontrol (A); 
2015 (B); 2025 (C). Abbreviations: CAR, Central African Republic; DRC, Democratic 
Republic of Congo; L. loa, Loa loa; mf, microfilariae.
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Figure 3 shows how the estimated prevalence of loiasis–on-
chocerciasis coinfection with L.  loa hypermicrofilaremia in 
L.  loa-mapped areas declines over time. Precontrol, we iden-
tified hot spots of coinfected L.  loa hypermicrofilaremic cases 
with prevalence rates between 6% and 12%, mainly in the 
Orientale province of DRC, Cameroon, and the CAR. For 2025, 
we predict that only some high prevalence foci will remain in 
the CAR, Cameroon, Gabon, and the Republic of Congo; al-
most all in untreated onchocerciasis-hypoendemic areas. For 
additional information, see Supplement S2.
Sensitivity Analysis
Figure 4 summarizes the results of the sensitivity analysis, 
showing the sensitivity of the predicted number of coinfected 
cases with hypermicrofilaremia over time with varying assump-
tions of the effect of MDA on loiasis. If we assume no impact of 
ivermectin on loiasis, the decline in the number of coinfected 
cases with hypermicrofilaremia is much slower than in our 
main analysis, and the opposite is true if we assume an expo-
nential effect of repeated treatment. The large difference in the 
number of cases between the 3 assumptions in 2015 is mainly 
due to the fact that the highest impact of ivermectin on infection 
is achieved after a first MDA round with ivermectin (both on 
L. loa intensity and prevalence), which obviously did not occur 
in the scenario of no effect of ivermectin on L.  loa. However, 
the number of cases under the latter assumption was predicted 
to decline more dramatically between 2015 and 2025, mainly 
thanks to the decline in onchocerciasis in the coinfected cases. 
Consequently, little difference remains between the assump-
tions in the predicted number of L.  loa hypermicrofilaremic 
coinfected cases by 2025.
DISCUSSION
We anticipate major reductions in the prevalence of O. volvulus 
(89.1%) and coinfection cases with L. loa hypermicrofilaremia 
(85.0%) between 1995 (precontrol) and 2025 in areas that are 
coendemic for loiasis and currently subject to ivermectin MDA 
(Table 2; Supplement S2, Table S2). We predict that by 2025, un-
treated onchocerciasis-hypoendemic areas will contain 77.1% 
of all remaining onchocerciasis-infected individuals, 65.3% of 
all L. loa hypermicrofilaremic cases, and 92.9% of all coinfected 
L. loa hypermicrofilaremic cases. Adapted policy recommenda-
tions are required for these areas.
An important policy question is what needs to be done in cur-
rently untreated areas. Some areas in our study are thought to be 
free of onchocerciasis (eg, untreated areas in Burundi, Chad, and 
Equatorial Guinea [24] but also scattered patches in some other 
countries). If this is confirmed by further elimination mapping, 
no onchocerciasis control measures are required. We also identi-
fied several onchocerciasis-hypoendemic areas in Ethiopia that 
are likely to be free from loiasis. If this is confirmed by further 
mapping, one can proceed with standard MDA. However, most 
problematic are onchocerciasis-hypoendemic areas coendemic 
with loiasis where a proportion of the population is still L. loa 
Figure 3. Maps showing the estimated prevalence of loiasis–onchocerciasis 
coinfections with L. loa hypermicrofilaremia (≥20 000 mf/mL) in L. loa-mapped areas 
coendemic for onchocerciasis for 3 time points: 1995, precontrol (A); 2015 (B); 2025 
(C). Abbreviations: CAR, Central African Republic; DRC, Democratic Republic of 
Congo; IVM, ivermectin; L. loa, Loa loa; mf, microfilariae; O.v., Onchocerca volvulus.
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hypermicrofilaremic. For these areas, a safe option would be 
to implement a TNT strategy aimed at excluding severely in-
fected individuals from treatment through testing of periph-
eral blood with a videomicroscope (LoaScope) [20]. According 
to our calculations, in 2015 about 14 million people lived in 
areas where TNT might be a suitable strategy for moving for-
ward with onchocerciasis elimination, of which 129 000 (0.9%) 
would be at high risk of SAEs following ivermectin treatment. 
The prevalence of L.  loa hypermicrofilaremia varies between 
onchocerciasis-hypoendemic areas, with predicted prevalences 
of <0.2% in Sudan and Nigeria and >5.0% in Gabon and the 
CAR. These results are in line with other published estimates 
[25–27]. In a recent TNT trial in Cameroon (2015 data), 2.1% 
of the screened individuals were excluded from ivermectin dis-
tribution due to L. loa mf density ≥20 000 mf/mL [20]. In our 
analysis, we predict that for L.  loa-endemic onchocerciasis-
hypoendemic areas in Cameroon, 3.9% of the population would 
need to be excluded from ivermectin during a TNT on the basis 
of L.  loa mf density ≥20  000 mf/mL blood. A  TNT strategy 
is costlier than standard MDA [28], which raises questions 
about the affordability of implementing TNT on a wide scale. 
A strategy for eliminating onchocerciasis in hypoendemic areas 
could potentially include community-directed vector control 
(eg, slash and clear vegetation [29], ground-based larviciding) 
to supplement TNT-based medication.
New or adapted safe drugs with macrofilaricidal activity that 
can potentially be used for mass distribution in L. loa coendemic 
areas should be considered. Current second-line treatments for 
usage in hypermicrofilaremic coinfected individuals have lim-
itations, that is, doxycycline needs to be taken daily for 4 to 6 
weeks, is age-restricted, and cannot be used in pregnant and 
breast-feeding women [30, 31], whereas moxidectin [32] is also 
likely contraindicated in patients with heavy L.  loa infections 
due to the risk of SAEs.
We estimate that by 2025 there will be more than 6 million 
L.  loa microfilaremic cases remaining that may require treat-
ment for loiasis infection. Loa loa may cause more harm than 
commonly suggested; infection can lead to various severe com-
plications, including cardiac fibrosis, encephalopathy (in the 
absence of treatment), pulmonary infiltrates, neurological and 
psychiatric disorders, and excess mortality [33, 34]. We pre-
dict that by 2025, 684 000 people living in nonendemic areas 
for onchocerciasis will be L. loa hypermicrofilaremic, justifying 
additional investments in research and drug development for 
treating L. loa infection.
The results presented here are estimates based on the most 
comprehensive available data, yet there are some uncertainties 
and assumptions. Our analysis uses baseline data (REMO and 
RAPLOA) that are relatively old. The distribution of infection 
and population may have changed in the meantime. Each of the 
2 rapid assessment surveys have their own specific challenges 
(eg, mode of assessment, selection of survey sites and partici-
pants, sample size requirements) [4, 35] that may have led to 
some imprecision in our estimates for certain geographical 
areas, for example, some previously identified hypoendemic 
areas might be free of onchocerciasis [36], but we expect that 
the main conclusion will remain the same.
ONCHOSIM simulated the impact of ivermectin in treated 
areas according to reported treatment history and future MDA 
scenarios. Although current mathematical models capture com-
munity infection dynamics throughout MDA effectively, any 
incorrect assumptions on MDA initiation year, overreporting 
of MDA coverage, or MDA implementation challenges would 
result in higher O.  volvulus mf and coinfected case estimates 
for 2015 and 2025. Similarly, based on a published transition 
matrix, we assume that MDA impacts L.  loa mf intensity and 
prevalence [17]. The robustness of these assumptions was as-
sessed through a sensitivity analysis and found to be in line with 
evidence from a recent study on the impact of repeated annual 
MDA with ivermectin on loiasis prevalence and intensity in 
Cameroon [19]. These data from Cameroon suggest that repeti-
tive use of ivermectin may exponentially impact L. loa intensity 
(and to a lesser extent prevalence), with the highest effect after 
the first round of treatment. Finally, in this analysis, we have not 
taken into account any spatiotemporal covariates, such as the 
impact of climate change or deforestation on Simulium spp. and 
Chrysops spp. vectors. Additional data on these covariates and 
Figure 4. Sensitivity of the estimated number of onchocerciasis–loiasis 
coinfected cases by year for the following assumptions regarding the impact of 
mass drug administration on loiasis: no effect of IVM: IVM has no effect at all on 
the intensity and prevalence of Loa loa hypermicrofilaremia; effect of first round 
of IVM: IVM causes a change in the L. loa mf count frequency distribution among 
the population that received a first IVM treatment; the resulting L.  loa mf count 
frequency distribution is sustained after subsequent treatment without any further 
changes; and exponential effect of IVM: IVM reduces the prevalence and intensity 
of L.  loa mf after each repeated treatment with IVM, resulting in an exponential 
effect of repeated treatments on L.  loa mf. Abbreviations: IVM,  ivermectin; mf, 
microfilariae.
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their impact on vector density and infection levels could further 
improve our predictions.
CONCLUSIONS
According to our estimates, MDA has a remarkable impact on 
onchocerciasis and loiasis coinfected cases across Africa since 
the start of mass distribution of ivermectin. The highest number 
of remaining coinfected cases with L. loa hypermicrofilaremia 
will be in onchocerciasis-hypoendemic areas that would benefit 
most from alternative treatment strategies, such as TNT or al-
ternative treatments.
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